Andrea Ranghino

Prof. Andrea Ranghino


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2021 in Case Reports in Nephrology and Dialysis
Verified
Journal Article
Open access
PDF file
FMFederica Maritati
Federica Maritati
MMMaria Ilaria Moretti
Maria Ilaria Moretti
VNValentina Nastasi
Valentina Nastasi
RMRoberta Mazzucchelli
Roberta Mazzucchelli
MMManrico Morroni
Manrico Morroni
ARAndrea Ranghino
Andrea Ranghino
Many reports have described a high incidence of acute kidney injury (AKI) among patients with COVID-19. Acute tubular necrosis has been reported to be the most common damage in these patients, probably due to hemodynamic instability. However, other complex processes may be involved, related to the cytokine storm and the activation of innate and adaptive immunity. Here, we describe a patient who developed an antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis with rapidly progressive glomerulonephritis and lung involvement and an antiphospholipid syndrome soon after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. After viral pneumonia was excluded by bronchoalveolar lavage, the patient has been treated with rituximab for amelioration of kidney function and resolution of thrombosis without any adverse event. We conclude that COVID-19 may trigger autoimmune diseases including ANCA-associated vasculitis. Thus, this diagnosis should be taken in consideration in COVID-19 patients, especially when they develop AKI with active urinary sediment. In addition, considering the relationship between these 2 diseases, SARS-CoV-2 infection should be excluded in all patients with a new diagnosis ANCA-associated vasculitis before starting immunosuppressive therapy.

1 October 2023 in Journal of Endourology
Verified
Journal Article
Closed access
CGCarlo Giulioni
Carlo Giulioni
VPVanessa Palantrani
Vanessa Palantrani
VSVirgilio De Stefano
Virgilio De Stefano
ACAndrea Cicconofri
Andrea Cicconofri
AAAngelo Antezza
Angelo Antezza
AGANDREA Benedetto GALOSI
ANDREA Benedetto GALOSI
Background Patients who have undergone renal transplant may have a concomitant Benign Prostatic Hyperplasia (BPH), a condition that can potentially hinder the recovery of the renal graft and necessitate surgical intervention. However, endoscopic treatment of BPH should be performed carefully due to the associated perioperative risks. We aimed to systematically assess the factors affecting surgical indications and perioperative outcomes of BPH surgical treatment in renal transplantation (RT) recipients. Methods: A systematic literature search was performed on 28th January 2023 using Scopus, PubMed, and EMBASE with no date limit. Preclinical and animal studies, reviews, letters to the editor, case reports, and meeting abstracts were excluded. Results: Eighteen papers were accepted and included. Clinical BPH has a high incidence rate after RT, particularly in elderly men. Secondary events associated with BPH, such as acute urinary retention and urinary tract infections, can lead to a gradual decline of renal graft function and patient survival. BPH surgery can prevent these events and guarantee improvements in serum creatinine levels, voiding parameters, and lower urinary tract symptoms. When the urine culture is negative, the transurethral resection of the prostate may be performed within one month of the initial procedure, particularly in older patients, more prone to develop voiding dysfunction. Alternatively, a transurethral incision of the prostate may be recommended for patients with smaller prostates who wish to preserve ejaculatory function. Data on comparative BPH surgical procedures are lacking. Conclusions: BPH surgery should be offered in RT recipients who develop bladder outlet obstruction due to BPH. Endoscopic treatment should be performed after a few weeks from RT to avoid further graft deterioration.

23 May 2025 in Case Reports in Nephrology and Dialysis
Verified
Journal Article
Open access
MMMaria Ilaria Moretti
Maria Ilaria Moretti
MLMarta Leporati
Marta Leporati
RMRoberta Mazzucchelli
Roberta Mazzucchelli
MLMarina Di Luca
Marina Di Luca
GMGiorgia Mandrile
Giorgia Mandrile
ARAndrea Ranghino
Andrea Ranghino
Primary hyperoxaluria Type 1 (PH1) is an inherited disease due to deficient activity of the liver enzyme AGT due to a mutation of the AGXT gene, leading to impairment in the glyoxylate metabolism with excessive oxalate urinary excretion (uOx) causing nephrolithiasis, renal failure and systemic oxalosis. Historical treatment in renal failure was a combined liver-kidney transplantation (CLKT) to restore a normal function of AGT enzyme, but in mutation fully responsive to pyridoxine an isolated kidney transplant (IKT) is feasible. Recently, RNA-interference (RNAi) agents such as lumasiran that reduce the oxalate synthesis in PH1 patients open new therapeutic challenges such as IKT irrespective of the type of AGXT gene mutation. Nevertheless, to decide for IKT instead of CLKT, clinicians must be aware of lumasiran efficacy. At present, the biomarker used to evaluate the lumasiran efficacy is the plasma oxalate (pOx). However, in dialyzed patients, pOx might be influenced by the release of oxalate from the deposits to the blood. We report the case of a PH1 36-year-old male patient who underwent IKT combined with lumasiran. Two years after transplantation, graft function is well without lithiasis nor nephrocalcinosis. 24-hour uOx is almost normal as well as pOx. Allograft biopsies at 1, 6, 12 and 22 months show negligible oxalate crystals deposits. The novelty of our case lies in the methods we adopted to evaluate the lumasiran efficacy during dialysis prior listing for IKT. Specifically, we decided to list the patient for IKT according to the high plasma levels of glycolate reached after lumasiran treatment together with the significant reduction of the pOx.

9 July 2024 in Kidney and Dialysis
Verified
Journal Article
Open access
PDF file
MVMauro Valente
Mauro Valente
FOFRANCESCA ORECCHIONI
FRANCESCA ORECCHIONI
FBFabiana Brigante
Fabiana Brigante
MMMaria Ilaria Moretti
Maria Ilaria Moretti
RMRoberta Mariani
Roberta Mariani
ARAndrea Ranghino
Andrea Ranghino
The Ralstonia species (RB) and Burkholderia species (BB) are bacteria responsible for nosocomial infections in frail patients such as hemodialyzed (HD) patients. Here, we report how we managed an outbreak caused by RB and BB that occurred in a dialysis unit. From the 7th to the 16th of April 2021, an infection due to RB and BB occurred in 7 out of 39 (17.9%) HD patients with central venous catheter (CVC). Disinfectants, CVC-lock therapy solutions, water by reverse osmosis unit (ROW) and dialysis concentrates were cultured, including the biofilm from the loading plastic tubes (LPTs) that connect the hemodialysis consoles (HCs) to the ROW delivery line. The antibiotic treatment was successful for all patients. RB and BB were isolated in the biofilm of 11/37 LPTs. Three out of 11 positive LPTs were associated with the infected patients. The ROW delivery line was modified to provide a whole disinfection with the HCs connected, avoiding the risk of new contamination of the LPTs. A filtration module of 0.01 mm was added prior to the ROW delivery line. Our experience suggests that outbreaks sustained by unusual bacteria such as RB and BB should be promptly investigated to treat the infected patients with the appropriate therapy and to identify the possible source of infection, making the needful changes to achieve a safer dialysis unit.

8 October 2026 in Kidney and Dialysis
Verified
Journal Article
Open access
PDF file
TITefik Islami
Tefik Islami
Marilena GregoriniMarilena Gregorini
Marilena Gregorini
MGMaria Antonietta Grignano
Maria Antonietta Grignano
ESEmma Diletta Stea
Emma Diletta Stea
MVMauro Valente
Mauro Valente
TRTeresa Rampino
Teresa Rampino
Drug-induced thrombotic microangiopathy (DiTMA) is a rare but potentially life-threatening condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ injury, most frequently involving the kidney. Diagnosis remains challenging due to nonspecific clinical features and the lack of disease-specific biomarkers. Fluoroquinolones are widely prescribed antibiotics, yet their association with DiTMA is underrecognized. We report two cases of thrombotic microangiopathy (TMA) following fluoroquinolone exposure. A comprehensive diagnostic work-up was performed to exclude primary TMA, infection-related causes, malignancy-associated TMA, and complement-mediated forms. A kidney transplant recipient developed hemolytic anemia and severe thrombocytopenia after levofloxacin exposure without kidney involvement, while a second patient developed severe acute kidney injury requiring kidney replacement therapy following ciprofloxacin treatment. ADAMTS13 activity was normal in both cases, and complement-mediated TMA was subsequently investigated. A heterozygous CFHR3-CFHR1 deletion was identified in the first case, although its significance in this setting remains uncertain. Drug causality was assessed using the Naranjo Adverse Drug Reaction Probability Scale, World Health Organization–Uppsala Monitoring Centre criteria, and the DiTMA score. Fluoroquinolones were discontinued, and supportive treatment was provided, followed by clinical and laboratory recovery without recurrence during follow-up. These cases illustrate heterogeneous TMA phenotypes following fluoroquinolone exposure but do not establish drug causality. Fluoroquinolones should be considered among potential triggers when the temporal relationship is compatible, while competing causes are carefully assessed.